What changed: Renal cell carcinoma
Every dated change on the records linked to Renal cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
June 2026 · 1
2026 · 3
- 2026ApprovalPembrolizumabPembrolizumab approved in US
Platinum-resistant PD-L1+ ovarian cancer; adjuvant RCC with belzutifan; with sacituzumab govitecan in 1L TNBC
- 2026GuidelineRenal cell carcinomaGuideline NCCN Kidney v3.2026: Small renal mass (<4 cm)
Active surveillance, partial nephrectomy (usually robotic), or thermal ablation depending on growth, comorbidity, and biopsy; renal mass biopsy increasingly used. (NCCN 2A)
- 2026MilestoneRenal cell carcinomaLITESPARK-022 positive and approved (adjuvant belzutifan + pembrolizumab); LITESPARK-012 first-line triplet falls short
A milestone in how this cancer is treated.
2024 · 2
2023 · 1
2021 · 3
- 2021ApprovalCabozantinibCabozantinib approved in US
First-line advanced RCC with nivolumab (CheckMate 9ER)
- 2021MilestoneRenal cell carcinomaBelzutifan approved
A milestone in how this cancer is treated.
- 2021MilestoneRenal cell carcinomaNivolumab-cabozantinib, lenvatinib-pembrolizumab, adjuvant pembrolizumab, belzutifan (VHL), tivozanib approved
A milestone in how this cancer is treated.